Dr. Wenham on Future Directions with Antibody-Drug Conjugates in Ovarian Cancer

Video

In Partnership With:

Robert Wenham, MD, MS, FACOG, FACS, discusses future directions with antibody-drug conjugates in the treatment of patients with ovarian cancer.

Robert Wenham, MD, MS, FACOG, FACS, a gynecologic oncologist and chair of the Gynecologic Oncology Program at Moffitt Cancer Center, discusses future directions with antibody-drug conjugates (ADCs) in the treatment of patients with ovarian cancer.

ADCs are a key focus for research in ovarian cancer, Wenham says. If a selective target can be identified on a cancer cell, a very toxic payload can be delivered in a way that had not been previously possible, leading to greater efficacy, which makes the use of ADCs attractive, Wenham explains. This has been examined in early studies, specifically folate receptor α (FRα), Wenham notes.

Currently, several studies are examining ADCs are ongoing, most of which are utilizing microtubule-disrupting agents, as their payload can target a host of different targets like MUC, mesothelin, tissue factor, FRα, and TIM-1, Wenham says. However, none of these targets are standard and still need to be properly examined, Wenham concludes.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
A panel of 4 experts on hematologic malignancies
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.